Literature DB >> 9733878

Protection of mice against lethal coxsackievirus B3 infection by using DNA immunization.

A Henke1, E Wagner, J L Whitton, R Zell, A Stelzner.   

Abstract

Vaccination with DNA and recombinant vaccinia viruses (rec.VV) has been studied with the coxsackievirus B3 (CVB3) model system. Plasmids encoding all structural proteins of CVB3, when injected intramuscularly, induced only low levels of virus-specific antibodies. However, DNA vaccination with the major structural protein VP1 protected 72.2% of mice from lethal challenge, whereas VP1 expressed by rec.VV was much less efficient.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9733878      PMCID： PMC110201     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  16 in total

1.  Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope.

Authors:  L S Klavinskis; J L Whitton; E Joly; M B Oldstone
Journal:  Virology       Date:  1990-10       Impact factor: 3.616

2.  DNA immunization can stimulate florid local inflammation, and the antiviral immunity induced varies depending on injection site.

Authors:  M Yokoyama; D E Hassett; J Zhang; J L Whitton
Journal:  Vaccine       Date:  1997-04       Impact factor: 3.641

Review 3.  Viral heart disease.

Authors:  R Kandolf; P H Hofschneider
Journal:  Springer Semin Immunopathol       Date:  1989

4.  Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection.

Authors:  L S Klavinskis; J L Whitton; M B Oldstone
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

5.  Molecular definition of a major cytotoxic T-lymphocyte epitope in the glycoprotein of lymphocytic choriomeningitis virus.

Authors:  J L Whitton; J R Gebhard; H Lewicki; A Tishon; M B Oldstone
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

6.  Induction of neutralizing antibodies by the coxsackievirus B3 virion polypeptide, VP2.

Authors:  S T Beatrice; M G Katze; B A Zajac; R L Crowell
Journal:  Virology       Date:  1980-07-30       Impact factor: 3.616

7.  High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis.

Authors:  J Fohlman; K Pauksen; B Morein; U Bjare; N G Ilbäck; G Friman
Journal:  Scand J Infect Dis Suppl       Date:  1993

8.  DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations.

Authors:  E F Fynan; R G Webster; D H Fuller; J R Haynes; J C Santoro; H L Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

9.  Detection of Coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy.

Authors:  N E Bowles; P J Richardson; E G Olsen; L C Archard
Journal:  Lancet       Date:  1986-05-17       Impact factor: 79.321

10.  Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques.

Authors:  S Chakrabarti; K Brechling; B Moss
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272
View more
  14 in total

1.  A genetically engineered attenuated coxsackievirus B3 strain protects mice against lethal infection.

Authors:  M Dan; J K Chantler
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

2.  Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection.

Authors:  M K Slifka; R Pagarigan; I Mena; R Feuer; J L Whitton
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  Mucosal co-immunization with AIM2 enhances protective SIgA response and increases prophylactic efficacy of chitosan-DNA vaccine against coxsackievirus B3-induced myocarditis.

Authors:  Dafei Chai; Yan Yue; Wei Xu; Chunsheng Dong; Sidong Xiong
Journal:  Hum Vaccin Immunother       Date:  2014-03-10       Impact factor: 3.452

4.  Direct ex vivo kinetic and phenotypic analyses of CD8(+) T-cell responses induced by DNA immunization.

Authors:  D E Hassett; M K Slifka; J Zhang; J L Whitton
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 5.  Role of RNA structure motifs in IRES-dependent translation initiation of the coxsackievirus B3: new insights for developing live-attenuated strains for vaccines and gene therapy.

Authors:  Amira Souii; Manel Ben M'hadheb-Gharbi; Jawhar Gharbi
Journal:  Mol Biotechnol       Date:  2013-10       Impact factor: 2.695

6.  Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis.

Authors:  A Henke; R Zell; G Ehrlich; A Stelzner
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Deletions within the 5'UTR of coxsackievirus B3: consequences for virus translation and replication.

Authors:  Isabelle P Hunziker; Christopher T Cornell; J Lindsay Whitton
Journal:  Virology       Date:  2006-11-03       Impact factor: 3.616

8.  Molecular analysis of the role of IRES stem-loop V in replicative capacities and translation efficiencies of Coxsackievirus B3 mutants.

Authors:  Manel Ben M'hadheb-Gharbi; Katherine M Kean; Jawhar Gharbi
Journal:  Mol Biol Rep       Date:  2007-11-20       Impact factor: 2.316

9.  Detection of enterovirus capsid protein VP1 in myocardium from cases of myocarditis or dilated cardiomyopathy by immunohistochemistry: further evidence of enterovirus persistence in myocytes.

Authors:  Hongyi Zhang; Yanwen Li; Dougal R McClean; Peter J Richardson; Richard Florio; Mary Sheppard; Karen Morrison; Najma Latif; Michael J Dunn; Leonard C Archard
Journal:  Med Microbiol Immunol       Date:  2003-11-22       Impact factor: 3.402

10.  Characterization of enterovirus isolates from patients with heart muscle disease in a selenium-deficient area of China.

Authors:  T Peng; Y Li; Y Yang; C Niu; P Morgan-Capner; L C Archard; H Zhang
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.